Phase 3 Trials Explore Pirtobrutinib in CLL/SLL and MCL
Researchers are investigating pirtobrutinib in patients with CLL, SLL, and MCL.
Lymphoma
LYMPHOMA
FEATURE
LATEST NEWS
Dose-Intensive Chemoimmunotherapy “Preferred” for Untreated PMBCL
Dose-intensive chemoimmunotherapy may be more effective than standard chemoimmunotherapy in PMBCL, a meta-analysis suggests.
Post-Transplantation Consolidation With Pembrolizumab Feasible in Patients With PTCL
Researchers sought to determine whether post-transplantation consolidation with pembrolizumab would be an option for patients with PTCL.
Loncastuximab Tesirine Elicits Lasting Responses in Relapsed/Refractory DLBCL
Loncastuximab tesirine produced durable responses in a phase 2 trial of patients with relapsed or refractory DLBCL.
Liso-Cel Demonstrates Meaningful Benefit as Treatment for Relapsed/Refractory FL
Researchers sought to determine whether liso-cel would lead to responses in patients with relapsed/refractory FL.
Liso-Cel Shows Efficacy in Relapsed/Refractory LBCL
Researchers sought to determine whether liso-cel would be effective in patients with relapsed/refractory LBCL.
Adding Metformin to R-CHOP Appears to Increase Complete Remission Rate in DLBCL
Researchers sought to determine whether adding metformin to R-CHOP would be safe and effective in patients with DLBCL.
Pivotal Trial Shows Meaningful Outcomes for Mosunetuzumab in Relapsed/Refractory FL
Researchers sought to determine whether mosunetuzumab monotherapy would improve outcomes in patients with relapsed/refractory FL.
Work Ability After Diagnosis in Survivors of Hodgkin Lymphoma
Researchers sought to determine the work ability for survivors of Hodgkin lymphoma after diagnosis.
Mitochondrial DNA Fraction Breaks Linked to Increased Risk of NHL
Patients who have more mitochondrial DNA fraction breaks have a higher risk of developing non-Hodgkin lymphoma, according to new research.
Optimal Fludarabine AUC Associated With Improved PFS After CD19 CAR-T Therapy in Aggressive NHL
Researchers sought to determine the optimal AUC dose for fludarabine and the impact it would have on PFS in patients with aggressive NHL.
Nicotinamide Supports NK Cellular Therapy in NHL
Researchers sought to determine whether expansion of NK cells with IL-15 and nicotinamide would improve responses in patients with NHL and MM.
Additional FDA Request Delays Decision on Reformulated Denileukin Diftitox
Denileukin diftitox is an engineered IL-2-diphtheria toxin fusion protein.
Pembrolizumab and Vorinostat Combination Shows Promise in Relapsed or Refractory PMBCL
Researchers sought to determine whether combination pembrolizumab and vorinostat would improve responses in patients with relapsed or refractory B-cell lymphomas.
Pembrolizumab Induces Long-Term Response in Relapsed, Refractory PMBCL
Researchers sought to determine whether pembrolizumab would induce long-term responses in heavily pretreated patients with relapsed or refractory PMBCL.
Zanubrutinib Deemed Safer Than Ibrutinib for Waldenström Macroglobulinemia
Zanubrutinib is as effective as — but safer than — ibrutinib for patients with Waldenström macroglobulinemia, a phase 3 trial suggests.
Pirtobrutinib Shows Efficacy Among Patients With CLL/SLL Who Have Received a Prior BTK Inhibitor
Researchers sought to determine whether pirtobrutinib would be effective in patients with CLL/SLL who progress after receiving treatment with a BTK inhibitor.
Body Composition Can Change During Chemo in Young Patients With Lymphoma, Rhabdomyosarcoma
Young patients with lymphoma or rhabdomyosarcoma may experience changes in body composition during chemotherapy, research suggests.
Relapse Timing Associated With Outcomes to Second-Line Therapy, Distinct Evolutionary Dynamics in DLBCL
Researchers sought to determine characteristics of late relapse in patients with DLBCL.
Pre-Existing Mental Health Disorders Associated With Lower Survival Rates in Older Patients Diagnosed With DLBCL
Researchers sought to determine the impact of mental health disorders on overall survival and lymphoma-specific survival in patients with DLBCL.
ASCO 2023: Lymphoma Research Could Change Practice
Studies presented at the ASCO Annual Meeting 2023 highlighted new developments in lymphoma that could lead to changes in practice.
Ibrutinib Fails to Improve PFS in Relapsed/Refractory FL or MZL
Researchers sought to determine whether ibrutinib would improve survival in patients with relapsed/refractory FL or MZL.
BrECADD Noninferior to eBEACOPP in Patients With Advanced-Stage Classical Hodgkin Lymphoma
Researchers sought to determine whether BrECADD would be as effective as eBEACOPP in patients with advanced-stage classical Hodgkin lymphoma.
Radiotherapy Can Be Omitted in Patients With PMBCL Who Achieve a Complete Metabolic Response After Immunochemotherapy
Researchers sought to determine whether it would be possible to omit radiotherapy in some patients with PMBCL.
AFM13 Shows Clinical Efficacy in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Researchers sought to determine whether AFM13 monotherapy would yield clinical activity in patients with relapsed/refractory peripheral T-cell lymphoma.
Data Support Liso-Cel for Relapsed or Refractory CLL/SLL
New research suggests that lisocabtagene maraleucel (liso-cel) is a potential treatment option for relapsed or refractory CLL/SLL.
Next-Generation BTK Inhibitor Orelabrutinib Shows Efficacy in Relapsed/Refractory MZL
Researchers sought to determine whether orelabrutinib would be effective in patients with relapsed/refractory MZL.
Intensified ABVD Bests PET-Adapted ABVD as First-Line Therapy for Hodgkin Lymphoma
Intensified ABVD can improve outcomes, when compared with PET-adapted ABVD, in patients with previously untreated Hodgkin lymphoma, a phase 3 study suggests.
Brentuximab Vedotin Plus Nivolumab, Doxorubicin, and Dacarbazine Shows Promising Activity in Early-Stage cHL
Researchers sought to determine whether adding brentuximab vedotin to nivolumab, doxorubicin, and dacarbazine would be a helpful first-line treatment for cHL.
Capivasertib Shows Promising Activity Against Relapsed/Refractory Follicular Lymphoma
Researchers sought to determine whether capivasertib would be an effective treatment for patients with relapsed/refractory follicular lymphoma.
HDC-ASCT Improves Survival vs Immunochemotherapy in Primary CNS Lymphoma
HDC-ASCT improves outcomes vs immunochemotherapy in newly diagnosed primary CNS lymphoma, a phase 3 study suggests.
Risk-Adapted Treatment Approach Produces Durable Remissions in MCL
A risk-adapted treatment approach can produce durable responses in younger patients with mantle cell lymphoma, a phase 2 trial suggests.
Acalabrutinib Plus Rituximab “Highly Effective” in Older MCL Patients
Acalabrutinib and rituximab can yield early complete responses in older patients with previously untreated mantle cell lymphoma.
Relapsed/Refractory Lymphoma Management Among Pregnant Patients Evaluated
Researchers sought to evaluate the management of relapsed/refractory lymphoma in pregnant patients.
IT and IV Methotrexate Produce Similar CNS Outcomes in DLBCL
Rates of CNS relapse are similar in DLBCL patients who receive high-dose IV methotrexate and those who receive IT methotrexate, phase 3 data suggest.
Columvi Approved for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed with a novel 2:1 structural format.
Most Lymphoma Patients Who Relapse During Pregnancy Can Have a Live Birth
A majority of lymphoma patients who relapse during pregnancy can have a live birth, even if treatment is initiated antenatally, a study suggests.
Gene Profiling Signature Identifies Dark Zone Lymphomas in a Real-World DLBCL Population
Researchers sought to determine the prevalence and outcomes of molecular subgroups in patients with DLBCL.
Potentially Targetable Feature Identified in Waldenström Macroglobulinemia
Researchers sought to analyze the immune microenvironment in Waldenström macroglobulinemia to determine any actionable targets.
CAR-T Therapy May Be Curative in Some Patients With LBCL
Researchers sought to determine whether CAR-T therapy with axi-cel would be effective long-term in patients with refractory LBCL.
Golidocitinib Yields Durable Antitumor Responses in Relapsed/Refractory PTCL
Researchers sought to determine whether golidocitinib would have antitumor response in patients with relapsed or refractory PTCL.
Atezolizumab, Obinutuzumab, Venetoclax Combination Induces Response in DLBCL-Richter Syndrome
Researchers sought to determine whether combination atezolizumab, obinutuzumab, and venetoclax would lead to responses in patients with the DLBCL variant of Richter syndrome.
Radiotherapy May Not Be Necessary After Chemotherapy in Some Patients With PMBCL
Researchers sought to determine whether radiotherapy could be avoided in patients with PMBCL following chemotherapy.
Comparable Early Outcomes Seen With Axi-Cel in Real-World, Trial Settings for Relapsed/Refractory Follicular Lymphoma
Researchers sought to determine whether axi-cel would have efficacy and safety for treating follicular lymphoma in a real-world setting compared with the ZUMA-5 trial.
Axi-Cel Shows Superior Overall Survival Data vs Standard of Care in LBCL
Researchers sought to determine whether axi-cel would improve overall survival rates in patients with LBCL.
Epcoritamab May Induce Durable Complete Responses in LBCL
Researchers sought to determine whether epcoritamab would be effective in patients with LBCL.
Copanlisib May Benefit Patients With Follicular Lymphoma
Researchers sought to determine whether copanlisib would have a response in patients with relapsed/refractory indolent follicular lymphoma.
Zilovertamab Vedotin Shows Clinical Activity in Relapsed/Refractory DLBCL
Researchers sought to determine whether zilovertamab vedotin would have antitumor activity in patients with relapsed/refractory DLBCL.
Racial Disparities Identified in Risk for SPMs in Patients With DLBCL
Researchers sought to determine risk of developing SPMs among patients with DLBCL based on race/ethnicity.
Superior PFS Seen With Nivolumab vs Brentuximab Vedotin in Advanced-Stage cHL
Researchers sought to determine whether nivolumab would improve PFS compared with brentuximab vedotin in patients with advanced-stage cHL.
Gut Microbial Dysbiosis May Play Role in R-CHOP Response in DLBCL
Researchers conducted rRNA and WGS sequencing to determine any link between gut microbial dysbiosis and R-CHOP treatment outcomes among patients with DLBCL.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
Loading... 
Loading...